A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no longer responds to hormone therapy. The study will measure the overall response (tumor shrinkage or disappearance) following treatment with JNJ-101556143.

Trial Details

NCT ID
NCT07832292
Phase
PHASE2
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • JNJ-101556143
Locations (sample)
  • Largo, Florida, United States|27.90979,-82.78842
  • Chicago Ridge, Illinois, United States|41.70142,-87.77922
  • Carmel, Indiana, United States|39.97837,-86.11804
  • Lafayette, Louisiana, United States|30.22409,-92.01984
  • Plymouth, Massachusetts, United States|41.95844,-70.66726

Key Eligibility Criteria

  • Have histologically confirmed adenocarcinoma of the prostate. Primary (or pathologic evidence of conversion to) small cell carcinoma, carcinoid tum…
  • Progressive metastatic androgen pathway modulation-resistant prostate cancer (mAPMR) defined as having a Prostate-Specific Antigen (PSA) level grea…
  • Prior bilateral orchiectomy or medical castration (receiving ongoing ADT with a Gonadotropin-Releasing Hormone (GnRH) analog \[agonist or antagonis…
  • Have discontinued concurrent use of any non-investigational systemic anticancer therapy (that is, cytotoxic chemotherapy, Androgen Receptor Pathway…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →